Antagonism of TLR9 in NASH and NASH-associated fibrosis could be an effective therapeutic strategy to target both the inflammatory and metabolic components of such a complex disease. This evidence concerns the gene TLR9 and metabolic dysfunction-associated steatohepatitis.